BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 18803412)

  • 1. Novel peptide linkers for highly potent antibody-auristatin conjugate.
    Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
    Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of linker stability to the activities of anticancer immunoconjugates.
    Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
    Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
    Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
    J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.
    Klussman K; Mixan BJ; Cerveny CG; Meyer DL; Senter PD; Wahl AF
    Bioconjug Chem; 2004; 15(4):765-73. PubMed ID: 15264863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
    Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.
    Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD
    Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.
    Temming K; Meyer DL; Zabinski R; Senter PD; Poelstra K; Molema G; Kok RJ
    Mol Pharm; 2007; 4(5):686-94. PubMed ID: 17683157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.
    Okeley NM; Miyamoto JB; Zhang X; Sanderson RJ; Benjamin DR; Sievers EL; Senter PD; Alley SC
    Clin Cancer Res; 2010 Feb; 16(3):888-97. PubMed ID: 20086002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker.
    Jeffrey SC; Nguyen MT; Moser RF; Meyer DL; Miyamoto JB; Senter PD
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2278-80. PubMed ID: 17293111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.
    Burke PJ; Toki BE; Meyer DW; Miyamoto JB; Kissler KM; Anderson M; Senter PD; Jeffrey SC
    Bioorg Med Chem Lett; 2009 May; 19(10):2650-3. PubMed ID: 19386499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin B Cleavage of vcMMAE-Based Antibody-Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific.
    Gikanga B; Adeniji NS; Patapoff TW; Chih HW; Yi L
    Bioconjug Chem; 2016 Apr; 27(4):1040-9. PubMed ID: 26914498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.